Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. (HARP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
harp · stock forecast · 9 analysts (3M) · FMP · updated Aug 9, 2024
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$700
Consensus
$700
+2942.2% upside
Low
$700
Median: $700 · Last Close: $23.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $23.03 | ↑ 0.08% |
1-day model range: $23.01–$23.04. Peak: $23.04 (+0.08%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HARP · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-04-03 | Canaccord Genuity | Maintains | Buy→Buy |
| 2023-03-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-12-14 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2022-11-15 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2022-11-15 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-08-29 | Citigroup | Maintains | Buy→Buy |
| 2022-08-23 | Truist Securities | Maintains | Buy→Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-08-11 | Piper Sandler | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Harpoon Therapeutics, Inc. (HARP) stock. Of the recent 29 rating actions, 2 were upgrades and 4 were downgrades. 9 analysts currently cover HARP.
Analyst Recommendation Trends
HARP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$38M
↑ 102.2% YoY
Revenue Next Year
$56M
↑ 45.9% YoY
EPS This Year
$-2.00
EPS Next Year
$-4.56
↑ 128.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast HARP EPS of $-2.00 for the current fiscal year, based on estimates from 8 analysts. The HARP revenue forecast is $38M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HARP stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HARP price target is $700.00 (+2942.2% upside), with an analyst consensus of Buy.
The HARP short-term stock prediction for tomorrow is $23.03 (+0.08%).
Harpoon Therapeutics, Inc. trades on NASDAQ under the ticker HARP. The HARP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 78% of covering analysts.
Frequently asked questions
HARP forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month HARP price target is $700.00, with a high forecast of $700.00 and a low of $700.00. The median price target is shown in the chart above when available. This implies +2942.2% potential upside from the current price of $23.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.